Recruiting Objective Response Rate of Ivonescimab With Chemotherapy in Locally Advanced Resectable Oral and Oropharyngeal Squamous Cell Carcinoma NCT07686575 Conditions Carcinoma, Carcinoma, Squamous Cell, HNSCC, +9 more Locations Department of Stomatology, Zhujiang Hospital, Southern Medical University, Haizhu District, Guangzhou — Guangzhou, Guangdong, China Department of Stomatology, Zhujiang Hospital, Southern Medical University,Haizhu District — Guangzhou, Guangdong, China View Trial Details
Recruiting Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma NCT06940518 Conditions Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +15 more Locations MD Anderson Cancer Center — Houston, Texas, United States View Trial Details
Recruiting A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC NCT07385001 Conditions Carcinoma, Carcinoma, Squamous Cell, Digestive System Diseases, +14 more Locations Tangdu Hospitial — Xi'an, Shannxi, China View Trial Details
Not Yet Recruiting AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal Cancer NCT07021950 Conditions Colonic Diseases, Colorectal Cancer, Colorectal Neoplasms, +10 more Locations Not specified View Trial Details
